滲出型加齢黄斑変性に対するペガプタニブ硝子体内投与の短期治療成績

Short-term outcome of intravitreal injection of pegaptanib for exudative age-related macular degeneration

要約　目的：滲出型加齢黄斑変性に対するペガプタニブの硝子体内投与から3～8か月間の結果の報告。対象と方法：滲出型加齢黄斑変性20例20眼を対象とした。男性9例，女性11例であり，年齢は42～81歳，平均66歳であった。ペガプタニブ0.3mgを硝子体内に投与し，3～8か月の経過を追った。視力はlogMARで評価し，0.3以上の変化を改善または悪化とした。結果：ペガプタニブの硝子体内投与は，9眼で1回，7眼で2回，4眼で3回行われた。最終視力は，5眼（25％）で改善，15眼（75％）で不変であり，悪化はなかった。黄斑体積の平均値は，術前と比較し1か月後と3か月後で有意に減少した（p＜0.05）。合併症はなかった。結論：滲出型加齢黄斑変性に対するペガプタニブの硝子体内投与から3～8か月の期間に，滲出性変化が改善し，全症例で視力が改善または維持された。

Abstract.　Purpose：To report the short-term outcome of intravitreal injection of pegaptanib for exudative age-related macular degeneration. Cases and Method：This retrospective study was made on 20 eyes of 20 cases of exudative age-related macular degeneration. The series comprised 9 males and 11 females. The age ranged from 42 to 81 years,average 66 years. Patients were followed up for 3 to 8 months after intravitreal injection of 0.3 mg pegaptanib. Visual acuity was evaluated in terms of logMAR. Change by 0.3 or more was interpreted as improvement or exacerbation. Results：Pegaptanib was injected once in 9 eyes,twice in 7 eyes and 3 times in 4 eyes. Final visual acuity improved in 5 eyes（25％）,remained unchanged in 15 eyes（75％）,and deteriorated in none. Mean macular volume decreased significantly 1 and 3 months after injection（p＜0.05）. Complication was absent throughout. Conclusion：Intravitreal injection of pegaptanib was followed by improved exudation and stabilized or improved visual acuity in eyes with exudative age-related macular degeneration after 3 to 8 months of treatment.